• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Low-Dose Edoxaban for Stroke Prevention in Elderly Patients with Atrial Fibrillation: Comment on the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) Trial.

作者信息

Liuzzo Giovanna, Patrono Carlo

机构信息

Associate Professor of Cardiology, Catholic University, Largo A. Gemelli, Rome, Italy.

Adjunct Professor of Pharmacology, Catholic University, School of Medicine, Italy and Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.

出版信息

Eur Heart J. 2020 Oct 21;41(40):3882-3883. doi: 10.1093/eurheartj/ehaa836.

DOI:10.1093/eurheartj/ehaa836
PMID:33067635
Abstract
摘要

相似文献

1
Low-Dose Edoxaban for Stroke Prevention in Elderly Patients with Atrial Fibrillation: Comment on the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) Trial.低剂量依度沙班用于老年房颤患者预防卒中：对依度沙班低剂量用于老年房颤患者（ELDERCARE-AF）试验的评论
Eur Heart J. 2020 Oct 21;41(40):3882-3883. doi: 10.1093/eurheartj/ehaa836.
2
Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.依度沙班用于不适合标准口服抗凝治疗的老年日本房颤患者的管理：老年房颤患者照护研究（ELDERCARE-AF）的原理与设计
Am Heart J. 2017 Dec;194:99-106. doi: 10.1016/j.ahj.2017.08.017. Epub 2017 Aug 24.
3
Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.低剂量依度沙班用于高龄房颤患者。
N Engl J Med. 2020 Oct 29;383(18):1735-1745. doi: 10.1056/NEJMoa2012883. Epub 2020 Aug 30.
4
Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.依度沙班在ENGAGE AF-TIMI 48试验中用于老年房颤患者的疗效及安全性
J Am Heart Assoc. 2016 May 20;5(5):e003432. doi: 10.1161/JAHA.116.003432.
5
Edoxaban in patients with atrial fibrillation.艾多沙班用于心房颤动患者。
Ther Adv Cardiovasc Dis. 2017 Mar;11(3):81-90. doi: 10.1177/1753944715622130. Epub 2016 Aug 1.
6
Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial.基于ENGAGE AF-TIMI 48试验结果比较依度沙班与华法林在房颤患者中的成本效益
Am Heart J. 2015 Dec;170(6):1140-50. doi: 10.1016/j.ahj.2015.09.011. Epub 2015 Sep 25.
7
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).新型 Xa 因子抑制剂依度沙班与华法林治疗心房颤动患者的比较评估：心房颤动-溶栓治疗心肌梗死 48 次新一代 Xa 因子有效抗凝试验（ENGAGE AF-TIMI 48）的设计和原理。
Am Heart J. 2010 Oct;160(4):635-41. doi: 10.1016/j.ahj.2010.06.042.
8
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.艾多沙班与华法林用于美国食品药品监督管理局批准人群中的非瓣膜性心房颤动患者：来自房颤新一代Xa因子有效抗凝-心肌梗死溶栓48（ENGAGE AF-TIMI 48）试验的分析
Am Heart J. 2016 Feb;172:144-51. doi: 10.1016/j.ahj.2015.11.004. Epub 2015 Dec 1.
9
Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.依度沙班对比华法林在伴有心房颤动和心力衰竭患者中的疗效和安全性：来自 ENGAGE AF-TIMI 48 的观察。
Eur J Heart Fail. 2016 Sep;18(9):1153-61. doi: 10.1002/ejhf.595. Epub 2016 Jun 28.
10
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.依度沙班剂量、浓度、抗 Xa 因子活性与结局的相关性：来自随机、双盲 ENGAGE AF-TIMI 48 试验的数据分析。
Lancet. 2015 Jun 6;385(9984):2288-95. doi: 10.1016/S0140-6736(14)61943-7. Epub 2015 Mar 11.

引用本文的文献

1
Laboratory Test Predictors for Major Bleeding in Elderly (≥80 Years) Patients With Nonvalvular Atrial Fibrillation Treated With Edoxaban 15 mg: Sub-Analysis of the ELDERCARE-AF Trial.依度沙班 15 毫克治疗非瓣膜性心房颤动的老年（≥80 岁）患者大出血的实验室检测预测因子：ELDERCARE-AF 试验的亚分析。
J Am Heart Assoc. 2022 Sep 6;11(17):e024970. doi: 10.1161/JAHA.122.024970. Epub 2022 Sep 3.
2
Effectiveness and Safety of DOACs vs. Warfarin in Patients With Atrial Fibrillation and Frailty: A Systematic Review and Meta-Analysis.直接口服抗凝剂（DOACs）与华法林在房颤合并虚弱患者中的有效性和安全性：一项系统评价和荟萃分析
Front Cardiovasc Med. 2022 Jun 24;9:907197. doi: 10.3389/fcvm.2022.907197. eCollection 2022.